Trial · NCT03451591
Results by group15
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 15 of 15
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Feasibility of Phase III Trial | Isosorbide Mononitrate XL (ISMN) | 20 | Participants | ||
| Feasibility of Phase III Trial | Cilostazol | 21 | Participants | ||
| Feasibility of Phase III Trial | ISMN XL and Cilostazol | 10 | Participants | ||
| Feasibility of Phase III Trial | Neither ISMN Nor Cilostazol | 4 | Participants | ||
| Trial Medication Tolerability Measured by Number of Participants With Adherence to Medication at Half Dose or More at 1 Year | Isosorbide Mononitrate XL (ISMN) | 59 | Participants | ||
| Trial Medication Tolerability Measured by Number of Participants With Adherence to Medication at Half Dose or More at 1 Year | Cilostazol | 48 | Participants | ||
| Trial Medication Tolerability Measured by Number of Participants With Adherence to Medication at Half Dose or More at 1 Year | ISMN XL and Cilostazol | 45 | Participants | ||
| Incidence of Treatment Emergent Adverse Effects [Safety] | Isosorbide Mononitrate XL (ISMN) | 1 | Participants | ||
| Incidence of Treatment Emergent Adverse Effects [Safety] | Cilostazol | 2 | Participants | ||
| Incidence of Treatment Emergent Adverse Effects [Safety] | ISMN XL and Cilostazol | 0 | Participants | ||
| Incidence of Treatment Emergent Adverse Effects [Safety] | Neither ISMN Nor Cilostazol | 1 | Participants | ||
| Treatment Efficacy - Percentage of Participants Experiencing an Event (Stroke, TIA, Myocardial Ischaemia, Cognitive Impairment and Dementia) | Isosorbide Mononitrate XL (ISMN) | 80 | Participants | ||
| Treatment Efficacy - Percentage of Participants Experiencing an Event (Stroke, TIA, Myocardial Ischaemia, Cognitive Impairment and Dementia) | Cilostazol | 84 | Participants | ||
| Treatment Efficacy - Percentage of Participants Experiencing an Event (Stroke, TIA, Myocardial Ischaemia, Cognitive Impairment and Dementia) | ISMN XL and Cilostazol | 36 | Participants | ||
| Treatment Efficacy - Percentage of Participants Experiencing an Event (Stroke, TIA, Myocardial Ischaemia, Cognitive Impairment and Dementia) | Neither ISMN Nor Cilostazol | 55 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03451591/results